CLINICAL TRIAL SUMMARY

MDACC Study No:ECOGE3F05 (clinicaltrials.gov NCT No: NCT00978458)
Title:Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Principal Investigator:John DeGroot
Treatment Agent:Radiation; Temozolomide
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if adding temozolomide to
radiation therapy can help to control low-grade glioma better than treatment
with standard radiation therapy alone. The safety of this treatment
combination will also be studied.

The radiation therapy in this study is designed to stop the reproduction and
repair of cancer cells by damaging the DNA (the genetic material of cells).
The damaged DNA may cause tumor cell death. Radiation therapy is the commonly
used standard of care for low-grade glioma.

Temozolomide is also designed to damage the DNA of cancer cells. The damaged
DNA may cause tumor cell death.

Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase III
Treatment Agents:Radiation
Temozolomide
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Eastern Cooperative Oncology Group/NCI Cancer Trials Support Unit (CTSU)
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:John DeGroot
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults